National Pension Service Acquires 8,264 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• National Pension Service increased its Regeneron stake by 2.2% in the second quarter, purchasing 8,264 shares and bringing its holdings to 379,815 shares valued at approximately $236.8 million. Institutional investors own 83.31% of REGN.
• Regeneron reported a strong quarter, with EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion, up 16.7% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $802.18, while HSBC raised its target to $920.
• Potential risks include a securities class-action lawsuit alleging inadequate disclosure of risks tied to the Fianlimab-Libtayo melanoma trial, as well as recent insider selling totaling 4,146 shares worth $3.43 million. The allegations remain unproven, and the insider transactions were conducted under 10b5-1 plans.

National Pension Service boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 379,815 shares of the biopharmaceutical company's stock after purchasing an additional 8,264 shares during the period. National Pension Service owned about 0.37% of Regeneron Pharmaceuticals worth $236,830,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $26,000. SHP Wealth Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $29,000. Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. Finally, Birchwood Financial Partners Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $32,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: HSBC raised its price target to $920 from $800 and maintained a Buy rating, implying additional upside based on the firm’s assessment of Regeneron’s prospects. HSBC price-target report
• Neutral Sentiment: A Wells Fargo healthcare-conference presentation and transcript offered investors additional management commentary, though the provided report does not identify a specific new catalyst. Wells Fargo healthcare conference transcript
• Neutral Sentiment: A report showing zero short interest is likely incomplete or erroneous, because it also reports a zero-day short-interest ratio and an undefined percentage change; it provides little actionable information for investors.
• Negative Sentiment: Several law firms repeated notices about a securities class action against Regeneron, with a September 14, 2026 lead-plaintiff deadline. The lawsuit concerns alleged failures to disclose risks surrounding the Phase 3 Fianlimab-Libtayo trial for melanoma, including statistical and protocol issues and possible effects of FDA Optimus-related amendments on progression-free-survival analysis. The allegations have not been proven. REGN class-action deadline notice
• Negative Sentiment: Reports that American Century Investments sold Regeneron shares may add to concerns about institutional conviction, although the available coverage does not provide the size or timing of the sale. American Century Investments sale report

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director directly owned 603 shares of the company's stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock valued at $3,432,488 in the last ninety days. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Trading Down 1.8%

Shares of REGN stock opened at $793.26 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a 50 day simple moving average of $752.38 and a two-hundred day simple moving average of $720.15. The company has a market cap of $81.67 billion, a P/E ratio of 19.61, a PEG ratio of 1.58 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the business earned $12.81 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Leerink Partners upped their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a "market perform" rating in a report on Monday, August 17th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. HSBC boosted their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a "buy" rating in a research report on Thursday. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Finally, Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. Fourteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $802.18.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.